From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.
Avid Bioservices, Inc. is expanding its CDMO service offering into the cell and gene therapy market: constructing a purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.
LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.
Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.
Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.
Boehringer Ingelheim has inaugurated a state-of-the-art biopharmaceutical production facility in Vienna, Austria: representing the single largest investment in the company’s history.
Fujifilm Irvine Scientific Inc has started the commissioning phase of its new 250,000 square feet (22,800 square meter) cell culture media manufacturing facility in Tilburg, the Netherlands; the site joins existing plants in the US and Japan.
ViroCell Biologics and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have formed a new partnership to immediately address the global viral vector manufacturing bottleneck for clinical trials
The biopharma industry continues to seek technologies that enable process control, while improving process development times and quality, says a Gamma Biosciences executive.
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
CureVac is streamlining its external European manufacturing network for its mRNA product pipeline; having reassessed demand for its first-generation COVID-19 vaccine candidate.
3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).
Sweden’s Biotage says its expanded facility in the UK will allow it to triple its production capacity for equipment crucial in the supply chain for the production of mRNA vaccines, and thus eliminating a bottleneck for COVID-19 vaccines.
Earlier this month, Rentschler Biopharma, a contract development and manufacturing organization (CDMO), announced that it had broken ground on its new production facility, adjacent to its existing site in Milford, Massachusetts, in the greater Boston...
VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....
The new facility will be home to Precision NanoSystems’s new global headquarters and include multiple GMP suites for manufacturing RNA therapeutics and vaccines.
Moderna has signed a Memorandum of Understanding with the government of Canada to build a mRNA vaccine manufacturing facility in the country: which could serve as a model for similar partnerships around the world.
CDMO AGC Biologics has acquired a commercial manufacturing facility in Longmont, Colorado: giving it significant additional capacity and space to expand its global end-to-end cell and gene therapy offering.
Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally
Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.
Boston headquartered biotherapeutics company, GentiBio, Inc, and CGT focused CDMO, Forge Biologics, have set up a development and manufacturing partnership.
Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.
Cobra Biologics, the gene therapy division of the Charles River owned Cognate BioServices, and Sweden's CombiGene recently announced the successful production and quality assurance of the plasmids to be used in the GMP production of the gene therapy,...
